Cargando…
Population pharmacokinetic modeling of molibresib and its active metabolites in patients with solid tumors: A semimechanistic autoinduction model
Molibresib (GSK525762) is an investigational, orally bioavailable, small‐molecule bromodomain and extraterminal (BET) protein inhibitor for the treatment of advanced solid tumors. Molibresib was initially evaluated in a first‐time‐in‐human (FTIH) study BET115521 consisting of two parts: Part 1 of th...
Autores principales: | Krishnatry, Anu Shilpa, Voelkner, Alexander, Dhar, Arindam, Prohn, Marita, Ferron‐Brady, Geraldine |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8302244/ https://www.ncbi.nlm.nih.gov/pubmed/33955700 http://dx.doi.org/10.1002/psp4.12639 |
Ejemplares similares
-
Exposure–response analysis of adverse events associated with molibresib and its active metabolites in patients with solid tumors
por: Krishnatry, Anu Shilpa, et al.
Publicado: (2021) -
A semimechanistic population pharmacokinetic and pharmacodynamic model incorporating autoinduction for the dose justification of TAS‐114
por: Araki, Hikari, et al.
Publicado: (2021) -
An Adaptive Physiologically Based Pharmacokinetic–Driven Design to Investigate the Effect of Itraconazole and Rifampicin on the Pharmacokinetics of Molibresib (GSK525762) in Healthy Female Volunteers
por: Riddell, Kylie, et al.
Publicado: (2020) -
A Phase I/II Open-Label Study of Molibresib for the Treatment of Relapsed/Refractory Hematologic Malignancies
por: Dawson, Mark A., et al.
Publicado: (2023) -
Phase 1 Study of Molibresib (GSK525762), a Bromodomain and Extra-Terminal Domain Protein Inhibitor, in NUT Carcinoma and Other Solid Tumors
por: Piha-Paul, Sarina A, et al.
Publicado: (2019)